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8 Although the prevalence of wild-type measles virus infection has decreased by
9 >90% in Europe, the disease is still not eliminated and has even reemerged with
10 recurrent outbreaks in different countries, including Romania and Italy. Minor out-
11 breaks of Romanian origin were reported from Hungary as well. In Romania, an
12 outbreak has been ongoing since February 2016. As of October 2017, 9,670 measles
13 cases and 35 deaths were registered in the country. The three most affected counties
14 are located next to the Hungarian border. In Italy, until the end of August 2017,
15 4,477 cases were reported to the surveillance system. The outbreak affected most of
16 the Italian administrative regions. Until October 2017, three minor measles outbreaks
17 were also detected in Hungary. All of these outbreaks were derived from Romanian
18 cases. Although in these countries, there are vaccination programs running, the spread
19 of the disease raises the possibility of secondary vaccine failure.
20 Keywords: Q3
21 Introduction
22 Measles virus (MeV) is the only member of the genus Morbillivirus that
23 causes human disease [1]. Measles is highly contagious, susceptible individuals
24 have a 99% probability of acquiring the virus, if they come in close contact with
25 the infected persons [1]. During the prevaccine era, more than 90% of patients
26 contracted the infection before 10 years of age. In unvaccinated populations, MeV
27 still causes periodic epidemics, with interepidemic period of 2–5 years [1]. The
28 basic reproduction number (R0 – deﬁned as the average number of secondary cases
29 of an infectious disease arising from a typical case in a totally susceptible
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30 population) for MeV is 12–18, which is one of the highest known values [2]. R0
31 also determines the herd immunity threshold and therefore the vaccination
32 coverage required to achieve elimination. As R0 increases, higher immunization
33 level is required in the population (Figure 1) [2]. In the case of measles, the critical
34 immunization threshold (qc) is about 94% based on the following formula:
35 qc= 1− 1/R0 (Figure 1) [2, 3].
36 In 2001, the World Health Organization (WHO) has launched a program to
37 eliminate measles [3]. This is promising, because MeV is a human-speciﬁc virus,
38 against which safe and potent vaccines are available [1]. Though the prevalence of
39 wild-type MeV infection has decreased by >90% in Europe, measles is still not
40 eliminated and has even re-emerged with recurrent outbreaks in different coun-
41 tries, including Romania and Italy. Minor outbreaks of Romanian origin were
42 reported from Hungary as well [4, 5]. As EU citizens can travel freely in these
43 countries, the chance of measles import into the neighboring areas increases. The
44 aim of this work is to shed light on the current epidemiologic situation in these
45 countries and on possible consequences for Hungary.
46 Situation in Romania
47 A measles outbreak in Romania has been ongoing since February 2016 [5].
48 As of October 2017, on the website of National Public Health Institute of Romania
F1:1 Figure 1.MeV basic reproduction number (R0), herd immunity, and immunization coverage. As R0
F1:2 increases, higher immunization coverage is needed to achieve herd immunity. Gray zone indicates
F1:3 the R0 estimate of 12–18, the characteristic value of measles [2]
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49 (INSP), 9,670 measles cases and 35 deaths were registered (http://cnscbt.ro/index.
50 php/informari-saptamanale/rujeola-1). Based on the data of this website, the
51 prevalence of laboratory-conﬁrmed cases, the incidence of new occurrences by
52 week, deaths, and mortality of the outbreak were calculated (Figure 2). The mean
53 mortality value is 0.44%, which is higher than usual in the developed countries [6].
54 Based on the data available on the website of INSP, 46% of deaths occurred
55 between 0 and 1 years of age, 40% between 1 and 10 years of age, and 14% of the
56 deceased were older than 10 years. In 60% of mortality, there were underlying
57 diseases detected. The cause of death was mostly pneumonia (91%). None of the
58 deceased was vaccinated.
59 The continuous outbreak is driven presumably by poor surveillance quality
60 and suboptimal population immunity [4]. The vaccination coverage in Romania is
61 below 90% [4].
F2:1 Figure 2. (A) Prevalence, (B) incidence, (C) value of calculated mortality, and (D) number of death
F2:2 cases of the ongoing measles outbreak in Romania
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62 Thirty-eight out of the 41 Romanian counties are affected with the disease
63 and in six of these, the morbidity rate per 100,000 people is higher than 99.01
64 (Figure 3). Among these six counties, three (Timis¸, Arad, and Satu Mare) are
65 located next to the Hungarian border (Figure 3).
66 Situation in Italy
67 In January 2017, the Italian National Health Institute (ISS) detected an
68 increase in the number of measles cases. ISS immediately started to intensify
69 surveillance and investigate the outbreak. Until the end of August 2017, 4,477 cases
70 were reported to the surveillance system, of which 76.3%were laboratory-conﬁrmed
71 [7]. The current outbreak affected most of the Italian administrative regions
72 (Figure 4) [7]. Based on the data of ISS, 88% of the cases were unvaccinated and
73 6.6% occurred among healthcare workers. Three deaths due to respiratory insufﬁ-
74 ciency were detected among children aged 16 months, 6 years, and 9 years,
75 respectively. All of them were unvaccinated. Measles was laboratory-conﬁrmed
76 in all of the deceased children [7]. Based on the data of the WHO Measles
77 Nucleotide Surveillance Database (MeaNS; www.who-measles.org), the strains
78 turned from D8 to B3 genotype at the beginning of 2017. Vaccination coverage
F3:1 Figure 3. Measles incidence per 100,000 people in Romanian counties in 2017
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79 is below 90% in Italy nowadays [7]. Decreased uptake of measles vaccine in the
80 country in recent years is the result of vaccine hesitancy.
81 The size of the described outbreak highlights that there are wide measles
82 immunity gaps in the Italian population, which is challenging to elimination [7].
83 The connection between the Romanian and Italian epidemics cannot be ruled out,
84 since in the MeaNS database, the same genotype (B3) was registered during 2017.
85 Consequences for Hungary
86 The measles vaccination program is very effective in Hungary, since the
87 introduction of the mandatory vaccination in 1969 [8]. In 1984, the administration
88 of the vaccine was postponed from 12 to 15 months of age, to provide more
89 permanent immunity. To further strengthen the immunological reaction, revacci-
90 nation was also ﬁrst organized in 1990 to decrease the number of persons without
F4:1 Figure 4. Measles incidence per 100,000 people in Italian provinces in 2017
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91 appropriate immune response [8, 9]. As a result of the vaccination program, more
92 than 99.5% of the population has been vaccinated, which eliminated the regular
93 circulation of MeV in Hungary [8, 9]. However, lifelong immunity after active
94 immunization is disputable due to primary or secondary vaccine failure [3, 10].
95 To support this, we examined the data about imported measles cases in the
96 literature in 2017. To our knowledge, until October, three minor measles outbreaks
97 were detected in the country. All of these outbreaks were derived from Romanian
98 cases.
99 The ﬁrst occurrences were detected from January 29, 2017 until March 10,
100 2017 in Mako´ and Szeged. During this period, 54 cases with measles-speciﬁc
101 clinical symptoms were reported [5]. About 15 cases were conﬁrmed and the
102 remaining 39 could be excluded by laboratory methods. Based on sequencing of
103 viral RNA genome, ﬁve cases revealed genotype B3 (data were kindly provided by
104 Dr. Zita Rigo´, National Reference Laboratory for Measles and Rubella, National
105 Public Health Institute, Budapest, Hungary), which were identical with the
106 Romanian and Italian genotypes based on the data of the MeaNS. Thus, the
107 connection with the Romanian epidemic seems to be supported. In consequence of
108 efforts and interventions, including active measles surveillance, quarantine,
109 isolation, aspeciﬁc preventive measures (medical examination, education, and
110 usage of protective equipment), observing in-patients, epidemiological monitoring
111 of healthcare workers, immunological screening, and post-exposure vaccination,
112 the public health ofﬁce could successfully terminate the occurrence of further
113 measles cases in Csongrád County. Of note, the high vaccination coverage
114 (>99%) of the Hungarian population also played an important role in this success
115 [8]. However, the spread of the disease among vaccinated healthcare workers
116 raises the possibility of secondary vaccine failure.
117 The second group of imported cases was detected at the end of July in
118 Nyíregyháza, Szabolcs-Szatmár-Bereg County. Six unvaccinated Romanian chil-
119 dren were admitted to hospital because of typical signs of measles. These cases
120 were also conﬁrmed by the National Reference Laboratory for Measles and
121 Rubella [11]. The disease could spread among the Hungarian population, since
122 the MeV infection of two healthcare workers (who were in close contact with the
123 Romanian children) was also conﬁrmed [11, 12].
124 The third group was consisted of four Romanian children, temporarily
125 staying in Bács-Kiskun County. The patients were 9, 11, and 13 months and
126 2 years of age, none of them were vaccinated. These cases were also conﬁrmed by
127 the National Reference Laboratory for Measles and Rubella [13, 14]. There was no
128 spreading detected among the Hungarian population [13, 14].
129 These data, in line with a recent study, raise the possibility of gaps in
130 population-level immunity against measles in Hungary [15]. Several reports describe
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131 a signiﬁcant proportion of secondary vaccine failure in populations with sustained
132 high vaccination coverage after long absence of MeV transmission with the resultant
133 lack of natural boosting, and waning of both the concentration as well as the avidity
134 of anti-measles IgG antibodies [10, 16–19]. Although avidity of antibodies may
135 slightly decrease with time, majority of the population with secondary vaccine
136 failure are characterized by antibodies of high-avidity index. Such outbreaks were
137 registered in Russia, Belarus, Germany, and Slovenia [10, 17, 18].
138 The ﬁnding that high proportions of secondary vaccine failure were detected
139 in countries with well working vaccination programs emphasizes the necessity of
140 studies assessing population immunity against MeV [10].
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